For the second year in a row my travel plans to the biopharmaceutical industry’s yearly kickoff event — the 35th Annual J. P. Morgan Healthcare Conference in San Francisco —was disrupted by weather. And though I once again arrived a day late, there was still plenty to keep me busy during JPM. For example, I still had the opportunity to sit in breakout Q&A sessions involving Alkermes, BMS, Chimerix, GSK, Mylan NV, and Shire. I witnessed company presentations that included AbbVie, CSL Limited, and IDEXX (just to name a few). I attended keynotes involving the Vice President of the United States, Joe Biden, who provided an update on the Cancer Moonshot initiative. I heard political consultants Karl Rove and James Carville debate the pros and cons of repealing and replacing the Affordable Care Act. I even had the opportunity to hear Juan Enriquez, co-author of Evolving Ourselves, share his insights on the next species of human. And while this may seem like a lot, it really only scratches the surface as to the amount of activity that takes place during JPM in January.
In 2002 Liz Lewis joined Takeda where she is currently chief counsel and head of patient advocacy at Takeda Oncology. Lewis sat down with me to share how she helped enhance Takeda Oncology’s patient advocacy organization.
Chief Editor Rob Wright talks with a few pharma industry icons about what to expect when seeking a board appointment.
In November 2015, Boehringer Ingelheim (BI) announced its new five-year R&D strategy, which included a commitment to invest $11 billion. Clive Wood, Ph.D., SVP of discovery research at BI, sat down with Life Science Leader to explain how the company is redefining its R&D strategy in order to maximize internal potential and expand research “for and beyond therapeutic area borders.”
So how does a lawyer become head of patient advocacy at one of the largest biopharma companies in the world? In Liz Lewis’s case, it started at the Washington, DC-based law firm, Epstein, Becker and Green where she represented healthcare and life sciences companies and served as cochair for the firm’s pharmaceutical practice group.
The executive-level participation for Life Science Leader magazine's signature 2017 Outlook issue had an overwhelming. This year’s feature article involved 13 executive life science leaders! In part four of this series, which is a supplement to the feature magazine article, we pose the question, “Looking even further ahead, what is your vision for how the global biopharmaceutical industry might look in the year 2027?”
The December 2016 issue of Life Science Leader magazine raised the bar in our 2017 Outlook feature article with participation from 13 trendsetters, including pharma leaders, payors, and a representative from the NIH. We hope you enjoy reading their thoughts in this supplement to the magazine’s December 2016 cover feature.
When Life Science Leader magazine asked for executive-level participation for the signature 2017 Outlook issue published in December 2016, we were overwhelmed with the response. This year’s feature article involved 13 executive thought leaders! In part two of this series, which is a supplement to the 2017 Outlook feature article, we pose the question, “What are you doing at your organization to address/capitalize on certain trends?”
When Life Science Leader magazine asked executives to participate in our signature 2017 Outlook issue published in December 2016, the response was overwhelming. We gained participation from 13 life science leaders! But one of the challenges such a positive response creates is it makes it impossible to publish all of this great content.
The sharing of this knowledge is meant not merely to provide you wisdom, but hopefully inspire insight.